MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561137 | Name: Vecabrutinib
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vecabrutinib, also known as SNS-062; FP-182, BSK-4841 and BIIB-062; is a potent, noncovalent, reversible BTK inhibitor that inhibits signaling through the BCR pathway. SNS-062 does not require interaction with BTK C481 for inhibitory activity. SNS-062 has improved PK properties over ibrutinib, including greater bioavailability and a longer half-life. SNS-062 may offer an alternative treatment option to patients with acquired resistance to ibrutinib.

Chemical Structure

Vecabrutinib
Vecabrutinib
CAS#1510829-06-7

Theoretical Analysis

MedKoo Cat#: 561137

Name: Vecabrutinib

CAS#: 1510829-06-7

Chemical Formula: C22H24ClF4N7O2

Exact Mass: 529.1616

Molecular Weight: 529.92

Elemental Analysis: C, 49.86; H, 4.57; Cl, 6.69; F, 14.34; N, 18.50; O, 6.04

Price and Availability

Size Price Availability Quantity
5mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1270014-40-8 (SNS062-analog) 1510829-06-7 1947403-49-7
Synonym
SNS-062; SNS 062; SNS062; FP182; FP 182; FP-182; BSK-4841; BSK4841; BSK 4841; BIIB-062; BIIB062; BIIB 062; Vecabrutinib.
IUPAC/Chemical Name
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxo[1,3'-bipiperidine]-4'-carboxamide
InChi Key
QLRRJMOBVVGXEJ-XHSDSOJGSA-N
InChi Code
InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)/t14-,15+,16-/m0/s1
SMILES Code
O=C1N([C@H]2CN(C3=NC=NC(N)=C3F)CC[C@@H]2C(N)=O)CCC[C@H]1NC4=CC(C(F)(F)F)=CC(Cl)=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 529.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Brown J, Mashima K, Fernandes S, Naeem A, Shupe S, Fardoun R, Davids M. Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL. Res Sq [Preprint]. 2024 Jan 16:rs.3.rs-3837426. doi: 10.21203/rs.3.rs-3837426/v1. PMID: 38313250; PMCID: PMC10836097. 2: Kim PM, Nejati R, Lu P, Thakkar D, Mackrides N, Dupoux V, Nakhoda S, Baldwin DA, Pei J, Dave SS, Wang YL, Wasik MA. Leukemic presentation and progressive genomic alterations of MCD/C5 diffuse large B-cell lymphoma (DLBCL). Cold Spring Harb Mol Case Stud. 2024 Jan 10;9(4):a006283. doi: 10.1101/mcs.a006283. PMID: 37730436; PMCID: PMC10815299. 3: Adam Z, Pour L, Zeman D, Krejčí M, Boichuk I, Krejčí M, Štork M, Sandecká V, Král Z. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow. Klin Onkol. 2023 Spring;36(3):177-191. English. doi: 10.48095/ccko2023177. PMID: 37353346. 4: Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022 Apr 1;107(4):984-987. doi: 10.3324/haematol.2021.280061. PMID: 34937320; PMCID: PMC8968902. 5: Jebaraj BMC, Müller A, Dheenadayalan RP, Endres S, Roessner PM, Seyfried F, Walliser C, Wist M, Qi J, Tausch E, Mertens D, Fox JA, Debatin KM, Meyer LH, Taverna P, Seiffert M, Gierschik P, Stilgenbauer S. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. Blood. 2022 Feb 10;139(6):859-875. doi: 10.1182/blood.2021011516. PMID: 34662393. 6: Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 2022 Jan 1;107(1):292-297. doi: 10.3324/haematol.2021.279158. PMID: 34498444; PMCID: PMC8719067. 7: Castillo JJ, Treon SP. Management of Waldenström macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):372-379. doi: 10.1182/hematology.2020000121. PMID: 33275726; PMCID: PMC7727571. 8: Iskierka-Jażdżewska E, Robak T. Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. Expert Opin Investig Drugs. 2020 Jul;29(7):709-722. doi: 10.1080/13543784.2020.1770225. Epub 2020 May 27. PMID: 32407139. 9: Iovino L, Shadman M. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. Curr Treat Options Oncol. 2020 Mar 13;21(4):24. doi: 10.1007/s11864-020-0715-5. PMID: 32170458. 10: Castillo JJ, Treon SP. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 Nov;33(11):2555-2562. doi: 10.1038/s41375-019-0592-8. Epub 2019 Oct 7. PMID: 31591468. 11: Bond DA, Woyach JA. Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205. doi: 10.1007/s11899-019-00512-0. PMID: 31028669.

View History

Icovamenib

Icovamenib